Combining anthracycline and taxane for early-stage operable breast cancer was more effective than either anthracycline or taxane chemotherapy alone in reducing breast cancer recurrence and death, ...

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when ...

Researchers have identified chromosomal instability in circulating tumour cells as a prognostic and predictive biomarker in ...

Chromosomal instability, which is a characteristic of many human cancers, contributes to intratumour heterogeneity and has been functionally implicated in resistance to taxane therapy in tumour models ...

Taxane-based radiochemotherapy is a central treatment option for various cancer entities in locally advanced stages. The therapeutic synergism of this combined modality approach due to taxane-mediated ...

Please provide your email address to receive an email when new articles are posted on . Women who use taxane chemotherapy agents may be at a higher risk to develop epiphora, optic neuropathy and ...

Taxanes have become front-line therapy for a variety of metastatic cancers, but resistance can develop, a frequent problem in breast, ovarian, prostate and other cancers. Now, researchers report a ...

The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers. Most physicians and investigators believe that taxane chemotherapy (paclitaxel, ...

Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity. MEDI-573 as a ...

Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)‑positive, unresectable, locally advanced or metastatic breast cancer in adults who ...

The combinations of docetaxel with anthracyclines are also highly active regimens for MBC. The dose-limiting toxicity observed in these regimens was myelosuppression. 30 However, doxorubicin/docetaxel ...

In a setback to US-based Abraxis Bioscience, the country’s patent office has refused to grant a patent to the company’s invention related to a combination of Taxane – a type of cancer drug that blocks ...